Study Supports Bimekizumab for Nonradiographic Axial Spondyloarthritis
The ongoing phase 3 BE MOBILE 1 study compared the efficacy and safety of bimekizumab to placebo in adults with active nr-axSpA.
Miscellaneous Musculoskeletal Disorders
New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Gene Therapy Gets Fast Track Status for Pain Associated With Osteoarthritis of Knee
XT-150 is a locally injectable non-viral therapy expressing interleukin (IL)-10v, a proprietary modified variant of IL-10.
Significant Improvements Seen With Bimekizumab in Ankylosing Spondylitis Trial
The ongoing phase 3 BE MOBILE 2 study compared the efficacy and safety of bimekizumab to placebo in 332 adults with active ankylosing spondylitis.
Xeljanz/Xeljanz XR Approved for Active Ankylosing Spondylitis
The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs.
AHA: Oral Milvexian Promising for Prevention of VTE
In patients undergoing knee arthroplasty, postoperative incidence of venous thromboembolism lower with milvexian versus enoxaparin
Steroid Injection No Better for Long-Term Carpal Tunnel Symptoms
At five years, no difference seen in symptoms, but rates of subsequent surgical treatment lower with methylprednisolone versus saline injection
Long-Term Bone Loss Studied in Postmenopausal Women
Lower baseline BMI and greater increase in BMI appear to be protective against postmenopausal bone loss
Data Support Upadacitinib in Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis
No new safety risks were identified in the studies.
Corticosteroid Injections in Hip Tied to Rapidly Destructive Hip Disease
Findings show dose-dependent association with risk higher for multiple injections or higher dose
